TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (K D =95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function.
性状
Solid
体外研究(In Vitro)
TPP-1 binds to PD-L1 with high affinity and blocks PD-1/PD-L1 interaction. The KD value of PD-L1 with TPP-1 peptide is about 95 nmol/L (around five times less than that with PD-1), The binding site of TPP-1 to PD-L1 is close to the interactive site of PD-1 and PD-L1.TPP-1 (4 μM) reactivates T-cell functions, it induces IFNγ release significantly higher than control and SPP-1, and the TPP-1 group shows similar outcomes for cell proliferation. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
TPP-1 (subcutaneous injection; 4 mg/kg; every other day eight times; 32 days) inhibits tumor growth (compared with SPP-1 and control). The growth rate in TPP-1-treated mice is 56%. And when administered in the absence of T cells (control group), TPP-1 has no effect on the growth of the H460-luc tumors. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Sealed storage, away from moisturePowder -80°C 2 years;-20°C 1 year
SequenceShortening
SGQYASYHCWCWRDPGRSGGSK
参考文献
[1]. Chunlin Li, et al. Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. Cancer Immunol Res. 2018 Feb;6(2):178-188.
溶解度数据
In Vitro: H2O : 50 mg/mL (20.09 mM; Need ultrasonic)配制储备液